Cargando…

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration

We investigated the efficacy of monthly alternating injections of aflibercept and bevacizumab (MAAB) for maintenance treatment in patients with neovascular age-related macular degeneration (AMD) who showed improvement with the initial monthly injections but presented with rapid worsening after conve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Junyeop, Kim, You Na, Kim, June-Gone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950741/ https://www.ncbi.nlm.nih.gov/pubmed/35329868 http://dx.doi.org/10.3390/jcm11061543

Ejemplares similares

Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab
por: Cao, Xuan, et al.
Publicado: (2023)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi, Sufian, et al.
Publicado: (2021)

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: You, Qi Sheng, et al.
Publicado: (2018)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
por: Moisseiev, Elad, et al.
Publicado: (2010)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
por: Hahn, Paul
Publicado: (2014)

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
por: Sato, Tomohito, et al.
Publicado: (2021)

Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
por: Schroeder, Marion, et al.
Publicado: (2022)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration
por: Park, Joo Youn, et al.
Publicado: (2011)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
por: Torabi, Hamidreza, et al.
Publicado: (2018)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Optical coherence tomography angiography biomarkers in a bi-monthly maintenance dosing aflibercept in patients with neovascular age-related macular degeneration
por: Park, Jong Beom, et al.
Publicado: (2023)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration
por: Nourinia, Ramin, et al.
Publicado: (2010)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
por: Itagaki, Kanako, et al.
Publicado: (2020)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample
por: Hussein, Zaid Rajab, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
por: Siempis, Thomas, et al.
Publicado: (2019)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
por: Riazi-Esfahani, Mohammad, et al.
Publicado: (2008)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010)

Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_elotn92o10cn52ve9ht9ul8rg5